Aragon Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Aragon Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Aragon Pharmaceuticals: 12 sponsored US clinical trials, none currently recruiting.
Aragon Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 4 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostatic Neoplasms, with 4 trials.
Top-decile sponsor footprint
Aragon Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
12 total, page 1 of 1
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02257736
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT02123758
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946204
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
NCT02578797
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
NCT02524717
Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927
NCT02230033
A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants
NCT02031666
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
NCT01790126
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
NCT01792687
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
NCT01171898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 1 |
| Phase 3 | 4 |
Therapeutic Areas
How the Aragon Pharmaceuticals early-phase archive is shaped
12 indexed studies, none listed as recruiting (0% open); 7 completed (58%).
Phase mix: 4 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Prostatic Neoplasms (4 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Aragon Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Aragon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Aragon Pharmaceuticals page
12 registered trials is a research-attention snapshot, not an endorsement of Aragon Pharmaceuticals or any single study.
- None of Aragon Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Prostatic Neoplasms is the condition Aragon Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostatic Neoplasms trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aragon Pharmaceuticals pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.